(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of -5.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Tango Therapeutics's revenue in 2025 is $42,069,000.On average, 5 Wall Street analysts forecast TNGX's revenue for 2025 to be $3,084,534,317, with the lowest TNGX revenue forecast at $2,594,589,360, and the highest TNGX revenue forecast at $4,548,098,932. On average, 4 Wall Street analysts forecast TNGX's revenue for 2026 to be $3,114,588,311, with the lowest TNGX revenue forecast at $2,558,913,756, and the highest TNGX revenue forecast at $4,548,098,932.
In 2027, TNGX is forecast to generate $4,145,937,582 in revenue, with the lowest revenue forecast at $3,395,668,825 and the highest revenue forecast at $4,896,206,338.